Working… Menu

A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01581463
Recruitment Status : Completed
First Posted : April 20, 2012
Last Update Posted : August 6, 2012
Information provided by (Responsible Party):
Ipe, LLC

Brief Summary:

Liothyronine is indicated for the treatment of primary hypothyroidism. Between 6 and 10 Million in the United States and 80 Million patients world-wide are hypothyroid, usually the result of autoimmune thyroiditis called Hashimoto's Disease. Hypothyroid symptoms result from low levels of thyroid hormones (T4 and T3) in the blood due to inadequate thyroid hormone production by the thyroid gland. Every tissue in the body is a thyroid hormone target and hypothyroid symptoms can be debilitating.

BCT303 utilizes Liothyronine, Sodium as the active ingredient, the same Liothyronine salt utilized as the active ingredient in currently marketed products.

The current "gold standard" for treatment of hypothyroidism are products containing Levothyroxine (T4). T4 is known to be a pro-hormone, converted to the more active hormone T3 by deiodinases in various tissues. Patients on Levothyroxine therapy alone are occasionally not euthyroid as measured by clinical presentation, a condition hypothesized to result from low levels of T3 from inadequate T4 to T3 conversion. In addition, the efficiency of conversion of T4 to T3 is variable and dependent on the patho-physiologic state of the patient.

BCT303 contains Liothyronine, Sodium as the active ingredient. This product has a patented formulation and granulation procedure that solves multiple clinical and stability problems associated with T3-based products. Thus, BCT303 is designed to have:

  1. Increased shelf stability to ensure the maintenance of claimed dosage.
  2. A sustained-release profile to minimize side effects associated with spikes in serum T3 levels.
  3. Uniformity of dose between production batches and between tablets.

Condition or disease Intervention/treatment Phase
Healthy Drug: Liothyronine, Sodium Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Single-Dose Study of the Pharmacokinetics of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects
Study Start Date : April 2012
Actual Primary Completion Date : August 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Liothyronine, Sodium
Healthy adults.
Drug: Liothyronine, Sodium
Single 100-microgram (2 X 50 microgram) dose.

Primary Outcome Measures :
  1. Serum Total T3 [ Time Frame: Four Days. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adults
  • Must be able to swallow tablets

Exclusion Criteria:

  • Hypothyroid Disease
  • Pregnant Females

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01581463

Layout table for location information
United States, District of Columbia
Georgetown University Hospital
Washington, District of Columbia, United States, 20007
Sponsors and Collaborators
Ipe, LLC
Layout table for additonal information
Responsible Party: Ipe, LLC Identifier: NCT01581463    
Other Study ID Numbers: BCT303
First Posted: April 20, 2012    Key Record Dates
Last Update Posted: August 6, 2012
Last Verified: August 2012
Keywords provided by Ipe, LLC:
pharmacokinetics of oral T3